FINAL REPORT
XI MEETING OF CICAD’S EXPERT GROUP ON DEMAND REDUCTION

DR. CARLOS RODRIGUEZ AJENJO
XI MEETING OF CICAD’S EXPERT GROUP ON DEMAND REDUCTION
Towards the Development of Comprehensive Public Policies on
Drug Treatment

Secretariat for Foreign Affairs
Mexico City, Mexico, September 29 - October 1, 2009

Final Report

CICAD’s Group of Experts on Demand Reduction was established by the CICAD Commission at its twenty-first regular session in 1997. Composed of experts nominated by each member state, it is an advisory body to the Commission on technical matters having to do with substance abuse prevention and treatment. The Expert Group’s remit includes developing models, programs and guidelines to address the many problems deriving from substance use and abuse in the hemisphere.

The eleventh meeting of the Expert Group on Demand Reduction was held in the Secretariat for Foreign Affairs, Mexico City, Mexico on September 29 – October 1, 2009 (see Annex I for the schedule of activities). The meeting was chaired by Dr. Carlos José Rodríguez Ajenjo, Technical Secretary of Mexico’s National Anti-Addictions Council (CONADIC), with Mrs. June Sivilli, Senior Advisor for International Demand Reduction, United States Office of National Drug Control Policy (ONDCP), Executive Office of the President, as Vice Chair. Participating were experts from Argentina, The Bahamas, Bermuda, Bolivia, Brazil, Canada, Chile, Costa Rica, Dominican Republic, Ecuador, Jamaica, Mexico, Panama, Trinidad and Tobago, United States, Uruguay and Venezuela. Representatives of the United Nations Office on Drugs and Crime (UNODC), the Latin American Federation of Therapeutic Communities (FLACT), the Ibero-American Network of NGOs working in Drug Dependence (RIOD), and the Mexican State-level Anti-Addictions Councils (CECAs) also participated (see Annex II for the list of participants and guest speakers).

Despite some progress in the hemisphere in improving drug treatment over the last twenty years, a significant gap remains between the number of treatment slots available and the need for treatment. This has led CICAD to encourage member states to give more priority to drug treatment in their national drug policies, to improve conditions in their treatment facilities, and to step up their training for treatment personnel. The goal is to offer treatment programs that are accessible and affordable, and, insofar as possible, integrated into the national health care system at all levels of care.

The objective of the meeting was to advance the development of evidence-based public policies in drug treatment, rehabilitation and aftercare (reinsertion) in the member states, and to develop a consensus on a body of recommendations, summarized in a declaration of principles on drug treatment, to guide member states in their efforts to improve the care given to drug users and drug-dependent persons in the hemisphere.
The opening session was addressed by Dr. Thomas McLellan, Deputy Director, ONDCP; Ambassador Lourdes Aranda Bezaury, Under Secretary, Secretariat of Foreign Affairs of Mexico; Ambassador James F. Mack, Executive Secretary, CICAD; Dr. Mauricio Hernández Ávila, Under Secretary for Prevention and Health Promotion, Mexican Health Secretariat, and Ms. Margarita Zavala, Chair of the Council of the Mexican National System for Comprehensive Development of the Family (DIF), who formally declared the meeting open.

On the first and third days of the meeting, the experts considered a draft document entitled *Basic principles of the treatment and rehabilitation of drug-abusing and drug-dependent persons in the hemisphere* (CICAD/DREX/doc.4/09.rev.2, at Annex III). A number of suggestions and recommendations were made to the document, and were incorporated by the Executive Secretariat. The document would remain open to comment by meeting participants until October 31, 2009.

The presentations, which can be found on CICAD’s website at: http://www.cicad.oas.org/Reduccion_Demanda/ENG/ExpertGroup.asp, and the discussions focused on five key areas of drug treatment, namely:

a. Policy development in drug treatment
b. Information as the basis for good policy
c. Screening and brief intervention in the primary health care system
d. Dual diagnosis
e. Social reintegration and recovery

The participants agreed to continue working in more detail on these issues and to set up small task forces which, between now and the next Expert Group meeting in the autumn of 2010, would produce technical working papers recommending certain courses of action to the CICAD Commission, and to member states. These topics would include: treatment protocols for specific population groups; strategies for screening and brief intervention as an alternative to indicated prevention; information systems as the basis for the design and evaluation of drug treatment policies; social integration (aftercare), training and certification of drug treatment personnel, and policy development, financing and advocacy for treatment in the member states.

The Expert Group also agreed that the agenda for its next meeting will continue to focus on drug treatment and rehabilitation (recovery), but would address some more practical approaches to implementation of a policy. Concrete successes would also be showcased.

Some ways in which members of the Expert Group promote better drug treatment in their countries were also discussed. These included:
1. Reviewing current standards of care in drug treatment in their own country, to
determine whether they need an update, whether it could be made mandatory
for drug treatment facilities to comply with the standards, and whether some
means of verification of compliance with the standards could be put in place.
2. Reviewing current policy on drug treatment, and determining that policy might
be expanded to reflect some of the points discussed in this meeting.
3. Improving the collection and analysis of information on patients in drug
treatment, working with the national observatory on drugs, for example.
4. Linking the work on drug treatment being doing at the national level with
efforts at the municipal level, through the EU-LAC city alliances project and
other decentralization efforts, such as SAVIA.

At the close of the meeting, Dr. Rodriguez Ajenjo, Mrs. Sivilli, and Ambassador
Oscar Maúrtua de Romaña, Representative of the OAS in Mexico, all addressed the
participants, and stressed the importance of the adoption of the \textit{Basic principles of the
treatment and rehabilitation of drug-abusing and drug-dependent persons in the
hemisphere}.

On behalf of the Executive Secretariat of CICAD, Dr. Anna Chisman, CICAD’s Head
of Demand Reduction, thanked the Government of Mexico, and CONADIC in particular, for
its generous contributions to the organization of the meeting, and its technical inputs to
the agenda items. She thanked the participants for bringing their expertise to bear on the
development of the \textit{Basic principles of the treatment and rehabilitation of drug-abusing
and drug-dependent persons in the hemisphere}, which would be presented to the forty-
sixth regular session of the CICAD Commission, to be held in November 2009 in Miami,
Florida, U.S.A.
INTRODUCTION

CICAD’s Group of Experts on Demand Reduction was established by the CICAD Commission at its twenty-first regular session in 1997. Composed of experts nominated by each member state, it is an advisory body to the Commission on technical matters having to do with substance abuse prevention and treatment. The Expert Group’s remit includes developing models, programs and guidelines to address the many problems deriving from substance use and abuse in the hemisphere.

Despite some progress in improving drug treatment over the last twenty years, a significant gap remains between the number of treatment slots available and the need for treatment. This has led CICAD to encourage member states to give more priority to drug treatment in their national drug policies, to improve conditions in their treatment facilities, and to step up their training for treatment personnel. The goal is to offer treatment programs that are accessible and affordable, and, insofar as possible, integrated into the national health care system at all levels of care.

Under the chairmanship of Mexico for the term of office 2009-2010, with the vice-chairmanship being held by the United States, the Expert Group is to develop a body of recommendations, which will be summarized in a Declaration of Principles on Drug Treatment, to guide member states in their efforts to improve the care given to drug users and drug-dependent persons in the hemisphere.
<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Participant Registration</td>
</tr>
<tr>
<td>09:00</td>
<td>Inaugural Session</td>
</tr>
<tr>
<td>09:00</td>
<td>Ambassador Lourdes Aranda Bezaury</td>
</tr>
<tr>
<td></td>
<td>Under Secretary</td>
</tr>
<tr>
<td></td>
<td>Foreign Affairs Secretariat, Mexico</td>
</tr>
<tr>
<td>09:00</td>
<td>Ambassador James F. Mack</td>
</tr>
<tr>
<td></td>
<td>Executive Secretary</td>
</tr>
<tr>
<td></td>
<td>Inter-American Drug Abuse Control Commission</td>
</tr>
<tr>
<td></td>
<td>Organization of American States</td>
</tr>
<tr>
<td></td>
<td>CICAD/OAS</td>
</tr>
<tr>
<td>10:00</td>
<td>Dr. Thomas McLellan</td>
</tr>
<tr>
<td></td>
<td>Deputy Director</td>
</tr>
<tr>
<td></td>
<td>Office of National Drug Control Policy</td>
</tr>
<tr>
<td></td>
<td>ONDCP, United States</td>
</tr>
<tr>
<td>10:00</td>
<td>Dr. Mauricio Hernández Ávila</td>
</tr>
<tr>
<td></td>
<td>Under Secretary for Prevention and Health Promotion</td>
</tr>
<tr>
<td></td>
<td>Health Secretariat, Mexico</td>
</tr>
<tr>
<td>10:00</td>
<td>Lic. Margarita Zavala</td>
</tr>
<tr>
<td></td>
<td>Chair</td>
</tr>
<tr>
<td></td>
<td>Council of the National System for Comprehensive Development of the Family</td>
</tr>
<tr>
<td></td>
<td>DIF, Mexico</td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:30</td>
<td>Introduction to the eleventh meeting of the Demand Reduction Expert Group</td>
</tr>
<tr>
<td></td>
<td>Towards the development of comprehensive public policies on drug treatment</td>
</tr>
<tr>
<td>10:30</td>
<td>This meeting of the Demand Reduction Expert Group is designed to prepare</td>
</tr>
<tr>
<td></td>
<td>guidelines that will help member states improve their drug treatment</td>
</tr>
<tr>
<td></td>
<td>services by developing comprehensive public policies on</td>
</tr>
</tbody>
</table>
treatment. The Chair and Vice Chair of the Group currently held by Mexico and the United States respectively, will discuss how the Group will work over the next two years to achieve this objective.

Dr. Carlos José Rodríguez Ajenjo, M.D.
Chair of CICAD’s Demand Reduction Expert Group
Technical Secretary
National Addictions Council
CONADIC, Mexico

Mrs. June Sivilli, M.A.
Vice Chair of CICAD’s Demand Reduction Expert Group
Senior Advisor International Demand Reduction
Office of Demand Reduction
Office of National Drug Control Policy
ONDCP, United States

Ambassador James F. Mack
Executive Secretary
Inter-American Drug Abuse Control Commission
Organization of American States
CICAD/OAS

11:00  11:20  Method of work for the Expert Group 2009-2010

• How will the various topics on the agenda for this meeting be addressed in the panels?
• What do we expect the outcome of the meeting to be?
• By what means can the Expert Group promote improvements in drug treatment in the member states?

Anna McG. Chisman
Head, Demand Reduction
Inter-American Drug Abuse Control Commission
Organization of American States
CICAD/OAS

11:20  11:45  Draft declaration on Principles of Drug Treatment

Drug use and its consequences are a serious public health problem that significantly affects the quality of life in our hemisphere. Recent research findings over the last few decades mean that we must refocus our drug treatment strategies to take account of good evidence and consensus expert opinion, and recommend that countries update their policies on treatment.
Key questions:

- What are the hemisphere's priorities in the area of treatment for problems associated with drug use?
- What progress has been made in the hemisphere in the development of policies on drug treatment?
- What should our approach be to treatment of drug abuse and dependence, bearing in mind that it is a chronic, relapsing disease?
- What are the essential components of a comprehensive policy on treatment?
- In light of current knowledge,
- How is the idea of treatment as a continuum of care matched to client needs related to cost-effectiveness criteria?

Dr. Carlos Rodriguez Ajenjo
Chair, CICAD’s Demand Reduction Expert Group
CONADIC, Mexico

11:45 12:30 Problems associated with drug use: an overview from the health perspective
Viewing drug use problems as “public health problems” means a recalibration by the Governments of the hemisphere. Issues such as the epidemiologic basis for decisions, a determination of the health burden associated with drug use, and the inclusion of drug treatment in national health plans are key to this process.

Dr. Mauricio Hernández Ávila
Under Secretary for Prevention and Health Promotion
Health Secretariat, Mexico

12:30 14:00 LUNCH

14:00 14:30 Hemispheric Approach to Public Policies in Drug Treatment
The implications of drug treatment on member states’ public policies in general must be examined. Questions such as the right to treatment, the allocation of government funds, the integration of drug treatment into the health care services, and respect for human rights must be raised in connection with drug treatment. CICAD is promoting a policy discussion of these issues on the basis of the best available evidence.

Key questions:

- How much importance is attached to drug treatment in the context of overall policy development in the hemisphere?
- How does this influence the type of services offered?
Why should the issue of treatment be linked to national policies?

Dr. Luis Alfonzo Bello, M.D.
Demand Reduction Specialist
CICAD/OAS

14:30  16:30  PANEL  1

Laying the groundwork for a drug treatment policy
Discussion of the formulation of a drug treatment policy based on specific experiences – principles, strategies, design and implementation, challenges and opportunities

Key questions:
• Which government departments or sectors should develop such a policy?
• Is there a road map for development and implementation of drug treatment policies?
• What are the essential elements of a comprehensive public policy on treatment?
• What are the obstacles to the development of policy in this area, and how can we overcome them?

Panelists

Dr. Bartolomé Pérez-Galvez
Director of the Provincial Drug Plan of Alicante, and Former Director General of Drug Dependence for the Community of Valencia
Spain

Lic. Eugenia Mata
Demand Reduction Coordinator
Institute for Drug Control (ICD)
Costa Rica

Moderator and comments

Dr. Mariano Montenegro
Director of Treatment
National Drug Council
CONACE, Chile

16:30  17:00  Coffee Break

17:00  18:30  Debate
Moderator

Dr. Mariano Montenegro
CONACE, Chile

18:30 Close

18:45 COCKTAIL RECEPTION HOSTED BY CICAD IN THE MINISTRY OF FOREIGN AFFAIRS

Wednesday, September 30

09:00 11:00 PANEL 2

Role of information systems in the development of drug treatment policies: what do we need to know?
Information systems have become a key part of policy development, both in design and in execution, evaluation and course correction.

Key questions:
• What kind of information is needed to design and implement a comprehensive policy on drug treatment?
• What are the indicators on drug treatment that we need to develop in the hemisphere?
• What sources do we need? Direct and indirect data.

Panelists

Dr. Francisco Cumsille
Chief of the Inter-American Observatory on Drugs
CICAD/OAS

Dr. Indalecio Carrera
Psychiatrist
Addiction Assistance Center of the City Association Against Drugs of ACALD A Coruña
Galicia, Spain

Mr. Terrance Fountain
Deputy Director
National Drug Observatory
National Antidrug Secretariat
Ministry of National Security
The Bahamas

**Moderator and comments:**

**Dr. Jorge Villatoro**  
Researcher  
National Psychiatric Institute "Dr. Ramón de la Fuente M.", Mexico

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td>11:30</td>
<td><strong>Debate</strong></td>
</tr>
<tr>
<td>12:30</td>
<td><strong>LUNCH</strong></td>
</tr>
<tr>
<td>14:00</td>
<td><strong>Debate (cont.)</strong></td>
</tr>
<tr>
<td>15:00</td>
<td><strong>PANEL 3</strong></td>
</tr>
</tbody>
</table>

**Screening and brief intervention strategies:**  
*A bridge to the health system?*  
Public resources assigned to drug treatment tend to be scant, and are largely devoted to financing specialized interventions. However, more than 90 per cent of drug users who need treatment either do not seek it, or do not receive it in timely fashion. Brief intervention is proposed as one option for increasing coverage at low cost, and also as a form of indicated prevention.

**Key questions:**

- *Is it possible to develop brief intervention strategies for drug use as well as alcohol use?*
- *How effective are these interventions?*
- *Is the primary health care system in our countries a good location*
for conducting brief interventions?

Panelists

Dr. Wilson Compton, MD., M.P.E.,
Director
Division of Epidemiology, Services and Prevention Research,
National Institute on Drug Abuse (NIDA), United States
Screening, Brief Intervention, Referral & Treatment (SBIRT)

Dr. Paulina do Carmo Arruda Vieira Duarte
Deputy National Anti-Drug Secretary
National Secretariat for Drug Policy
SENAD, Brazil
System for the detection of the abuse, use of and addiction to psychoactive substances: Referral, brief intervention, social rehabilitation and follow-up (SUPERA)

Moderator and comments:

Dr. Carlos José Rodríguez Ajenjo
CONADIC, México

16:00 16:30 Coffee Break

16:30 18:30 Debate

Moderator

Dr. Carlos José Rodríguez Ajenjo
CONADIC, México

18:30 Close

19:00 RECEPTION HOSTED BY THE GOVERNMENT OF MEXICO
Problems associated with drug use in the context of public health policies
Drug abuse and dependence are very significant complications of drug use, but are not the only ones. Drug use is often associated with mental disorders and physical problems such as infections or lesions, which represent a serious problem for diagnosis and treatment.

Key questions:
• In addition to abuse and dependence, what other problems associated with drug use are having a major impact on the health systems of the countries of the hemisphere?
• What is the state of the art in treating these co-occurring disorders?
• What are the implications of co-occurring disorders from the epidemiological standpoint?

Panelists

Dr. Carlos José Rodríguez Ajenjo
CONADIC, Mexico
Medical Co-morbidity (infections and lesions)

Dr. Winston de la Haye, M.D.
Department of Community Health and Psychiatry
University of the West Indies
Psychiatric Co-morbidity

Moderator and comments

Ms. Harlie Outhwaite
Research Analyst,
Office of Demand Reduction
Health Canada

10:45 11:15 Coffee Break

11:15 12:30 Debate

Moderator
Challenges for policies on post-treatment aftercare

Aftercare (or “social reintegration”) plays a crucial part in reducing the impact of drug use and in the medium- and long-term prognosis for people receiving treatment. However, the subject is relatively under-developed in the hemisphere.

Key questions:

• What are the principal psychosocial complications of substance use in the countries of the hemisphere?
• What should our strategies be for developing public policies on aftercare?
• Is it possible to integrate aftercare into our countries’ other social policies?
• How can international cooperation help in this area?

Panelists

Dr. Mariano Montenegro
CONACE, Chile

Dr. Westley Clarke, J.D., M.D.
Director, Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA), United States
Access to Recovery – Reentry, Treatment, Recovery and Social Services Support

Moderator and comments

Mrs. June Sivilli, M.A.
Vice Chair of CICAD’s Demand Reduction Expert Group
Vice Chair of CICAD’s Demand Reduction Expert Group
ONDCP, United States

17:45  18:15   Conclusions and Recommendations
Principles of drug treatment

18:15  18:30   Close of the meeting

Amb. Oscar Maúrtua de Romaña
Representative
Office of the OAS in México

Mrs. June Sivilli
Vice Chair of CICAD’s Demand Reduction Expert Group

Anna Chisman
Head, Demand Reduction
CICAD/OAS

Carlos José Rodríguez Ajenjo
Chair of the Demand Reduction Expert Group
CONADIC, Mexico
LISTA DE PARTICIPANTES/
LIST OF PARTICIPANTS

Ciudad de México
Septiembre 29 – Octubre 1 de 2009
ARGENTINA

Lic. Karina Casal
Directora Nacional de Prevención y Capacitación
Prevención de la Drogadicción y la Lucha contra el Narcotráfico (SEDRONAR)
Buenos Aires, Argentina
Tel: (54-11) 4320-1200 int.1182
Fax: (54-11) 4320-1212
casal@sedronar.gov.ar

Dr. Carlos Vizzotti
Prevención de la Drogadicción y la Lucha contra el Narcotráfico (SEDRONAR)
Buenos Aires, Argentina
Tel: (54-11) 4320-1200 int.2349
Fax: (54-11) 43201244
cvizzoti@sedronar.gov.ar

THE COMMONWEALTH OF THE BAHAMAS

Dr. Nelson Clarke
Psychiatrist
Head of Treatment and Drug Rehabilitation
Sandilands Rehabilitation Center
Nassau, Bahamas
Tel. (242) 364 9603
(242) 3243068
nelsonac@coralwave.com

BERMUDA

Dr. Ken Garfield Douglas
Department for National Drug Control
Bermuda
Tel. 441 505 4037

BOLIVIA

Reynaldo Molina Salvatierra
Asesor General del Viceministerio de Defensa Social y Sustancias Controladas
Peggy Maldonado Riss  
Primer Secretario de la Embajada de Bolivia en México.  
Tel. 525 5360 /30 ext. 15  
embajada_comercial@embol.org.mx

---

**BRASIL**

Dra. Lic. Paulina Duarte  
Secretaria Adjunta  
Secretaría Nacional de Políticas sobre Drogas  
paulina@planalto.gov.br

Rogério Ghesti  
Jefe de Gabinete  
Asesor Internacional  
Tel. (61) 3411 2995  
rogeiro.ghesti@planalto.gov.br

---

**CANADA**

Ms. Harlie Outhwaite  
Research Analyst  
Office of Demand Reduction  
Health Canada  
Tel: 613-941-0026  
Fax: 613-957-1565  
harlie_outhwaite@hc-sc.gc.ca

---

**CHILE**

Dr. Mariano Montenegro Corona  
Director Área Técnica en Tratamiento y Rehabilitación  
Consejo Nacional para el Control de Estupefacientes (CONACE)  
Tel: (56-2) 5100-816  
Fax: (56-2) 6974 - 973  
mmontenegro@conace.gov.cl
**COSTA RICA**

Lic. Eugenia Mata  
Coordinadora de Reducción de la Demanda  
Instituto Costarricense sobre Drogas - ICD  
Tel: (506) 524 276982  
emata@icd.go.cr

Giselle Amador Muñoz  
Directora General  
Instituto sobre Alcoholismo y Farmacodependencia IAFA.  
Tel: 506 88399359  
506 22244096  
gamador@iafa.go.cr  
giselleamador@gmail.com

**ECUADOR**

Ab. Carla Hidalgo Rivera  
Subsecretaria de Coordinación Internacional  
Tel. (593 – 2) 225 0126/0089/0892  
Cel. (09) 415 1353  
hidalgoc@minjusticia-ddhh.gov.ec

**MEXICO**

Dr. Carlos José Rodríguez Ajenjo  
Secretario Técnico del Consejo Nacional contra las Adicciones (CONADIC) de la Secretaría de Salud  
Tel: (5255) 5207-9936/91  
crodriguez@salud.gob.mx

Dr. Jorge Villatoro  
Instituto Nacional de Psiquiatría “Dr. Ramón de la Fuente M.” México

Dr. Angel Prado García  
Director General Adjunto de Operación y Patronatos  
Centros de Integración Juvenil  
Tel. (52 - 55) 5999 4949  
Fax. (52 – 55) 5999 – 7764
aprado@cij.gob.mx

José Manuel Castrejón Vacio
CONADIC
jmcastrejon@conadic.gob.mx

Alejandra Pérez de León
CONADIC
ale_pdeleon@yahoo.com

Armando Patrón
CONADIC
Distrito Federal

Maria Isabel Sirnes Mancera
CONADIC
Distrito Federal

Emilio Serrano
CONADIC
Distrito Federal

Leticia Cruz Rodríguez
CONADIC
Distrito Federal

Diego Roberto López Oviedo
CONADIC
Distrito Federal

Patricia Ortiz García
CONADIC
Distrito Federal

Maria Guadalupe Corona Uscanga
CONADIC
Distrito Federal

Lizbeth Roberta García Quevedo
CONADIC
Distrito Federal

Mónica Vínicara Vázquez
CONADIC
Distrito Federal

Simón Tavera Romero
CONADIC
Distrito Federal

Ana Lilia Oropeza Romero
CONADIC
Distrito Federal
ana.oropeza@salud.gob.mx

Luz María García Rivas
Procuraduría General de la Republica
CENAPI
Distrito Federal

Karina Alor Aguilar
Consejo Estatal Contra las Adicciones
Veracruz

Maria Begoña Hernáiz
ECCA de México
Distrito Federal

Marisol C Ramírez
Servicios de Atención Psiquiátrica
Distrito Federal

Jaime Ponce Alcocer
Consejo Nacional Contra las Adicciones
Querétaro

Jorge Sánchez
FEMEXCOT
Veracruz

Edgar Lozano Becerra
Consejo Estatal Contra las Adicciones
Chihuahua

Maria Guadalupe Torres Cepeda
Consejo Estatal Contra las Adicciones
Coahuila

Estela A. Pantejo E. de los M
CAIPAAC

Alejandro Madrigal Z.
SS
Tabasco
Eliseo Pérez Sánchez  
Consejo Estatal Contra las Adicciones  
Puebla 

Raúl Martín del Campo Sánchez  
Consejo Estatal Contra las Adicciones  
Estado de México 

German León  
Consejo Estatal Contra las Adicciones  
Sinaloa 

Clara Feliz Bautista  
Instituto Nacional de Psiquiatría  
Ciudad de México 

Carlos Escamilla  
Consejo Estatal Contra las Adicciones  
Chiapas 

Jaime Dávila  
Consejo Estatal Contra las Adicciones  
Morelos 

Lorena Sánchez Toledo  
Consejo Estatal Contra las Adicciones  
Guanajuato 

Ana Laura Solís Martínez  
Consejo Estatal Contra las Adicciones  
Oaxaca 

Tony Maldonado  
Consejo Estatal Contra las Adicciones  
Michoacán 

Berenice Santamaría González  
PGR – CENAPI  
Distrito Federal 

Diana R. Calderón Sánchez  
ISSSTE  
Distrito Federal 

Rosaura del Carmen González Castillo  
SSA Consejo Estatal Contra las Adicciones  
Campeche
Martha Palencia
SSA Consejo Estatal Contra las Adicciones
Durango

Paulino Sánchez Ávila
Drogadictos Anónimos
Distrito Federal

Paulina Sofía Tovar Reyes
Instituto de Asistencia e Integración Social (IASIS)
Distrito Federal

Joaquín Eugenio del Bosque
Hogar Integral de Juventud
Distrito Federal

Sandra Tovar Kuri
Picas y Platicas AC
Distrito Federal

PANAMA

Jazmín Bósquez Bóquez
Encargada de Reducción de la Demanda
Secretaría Ejecutiva
Comisión Nacional para el Estudio y la Prevención de los Dileitos Relacionados con Drogas, CONAPRED
Tel. 507 3252
Jazmin.bosquez@procuraduria.gob.pa

REPUBLICA DOMINICANA

Lic. Diógenes Checo Valera
Tel: (809) 2214747 Ext. 258 – 268
diogenescheco@gmail.com

TRINIDAD Y TOBAGO

Paul Holder
Coordinator NADAPP
Tel: 1(868) 627-3506/3527
625-7055 (direct)
Fax: 1(868) 627-4471
paul_030@hotmail.com

UNITED STATES

Dr. Andrew Tom McLellan
Deputy Director
Office of National Drug Control Policy (ONDCP)
Executive Office of the President
Tel: (202) 3956627

Ms. June Sivilli,
Senior Advisor for International Demand Reduction
White House Office of National Drug Control Policy (ONDCP)
Executive Office of the President
Tel: 202-395-5526 (direct)
jsivilli@ondcp.eop.gov

Dr. Wilson Compton, MD., M.P.E.,
Director
Division of Epidemiology, Services and Prevention Research,
National Institute on Drug Abuse (NIDA), United States

Dr. Westley Clarke JD., MD,
Director
Center for Substance Abuse Treatment (CSAT)
Substance Abuse and Mental Health Services Administration
(SAMHSA), United States
Tel. (202) 276 1660
westley.clark@samhsa.hhs.gov

Mr. Javier M. Córdova
Senior Analyst for Demand Reduction, U.S. Department of State
International Narcotics and Law Enforcement Affairs (DOS/INL).
Tel. (202) 312 9696
cordovajm@state.gov
VENEZUELA

Lic. Rafael Sánchez  
Director de Reducción de Demanda  
ONA  
Tel. 58 212 957 3461/68  
rsanchez@ona.gob.ve

URUGUAY

Dr. Gabriel Rossi  
Jefe del Área de Tratamiento de la Secretaría Nacional de Drogas  
Tel. 5982 15 03 935  
Movil. (598) 99 128 501  
grossi@presidencia.gob.uy

ORGANIZACIONES INTERNACIONALES / INTERNATIONAL ORGANIZATIONS

OFICINA DE LAS NACIONES UNIDAS CONTRA LA DROGA Y EL DELITO

Sr. Antonio Mazzitelli  
Representante UNODC México

Sra. Melva Ramírez  
Coordinadora de Proyectos

FEDERACION LATINOAMERICANA DE COMUNIDADES TERAPEUTICAS

Padre Gabriel Antonio Mejía  
Tel. 57 4 284 4304  
Fax. 57 4 254 9902  
flact@une.net.co

RED IBEROAMERICANA DE ONG QUE TRABAJAN EN DROGODEPENDENCIAS –RIOD

Angela Tello G.  
Coordinadora Nodo Andino de la RIOD  
Tel. 572 337 1633  
Cel. 57 314 8906514  
Fax. 572 337 1633  
angelatello@corporacionviviendo.org  
alunatello@gmail.com
INVITADOS ESPECIALES

Mr. Terrance Fountain
Deputy Director
Bahamas National Anti Drug Secretariat
Ministry of National Security
Tel: 1-242-326-4118/23/27
Fax: 1-242-326-1462
fountant@yahoo.com
Bahamas

Dr. Bartolomé Pérez-Galvez
Director de Plan de Drogas Provincial de Alicante
Ex- Director General de Dependencia de Drogas para la Comunidad Valenciana
bperezgalvez@ono.com
España

Dr. Indalecio Carrera
Médico-Psiquiatra
Dispositivo Asistencial de Adicciones de la Asociación Ciudadana de Lucha Contra las Drogas (ACLAD) de A Coruña
indaleciocarrera@mundo-r.com
Indalecio.carrera@asoc.aclad.es
Galicia, España

Dr. Winston de la Haye
Departament of Psychiatry and Community Health
University of the West Indies
wdelah@yahoo.com
Jamaica

Dr. Angel Alvarez MA, Ph.D
Polítólogo
Director del Instituto de Estudios Políticos
Universidad Central de Venezuela
Tel. (58 – 212) 6052306
angelalvarez@gmail.com
Carcas, Venezuela
SECRETARIA GENERAL DE LA ORGANIZACIÓN DE LOS ESTADOS AMERICANOS

Embajador Oscar Maúrtua de Romaña
Representante de la OEA en México
Tel. + (52-55) 5280 1147
Fax. + (52-55) 5281 7390
omaurtua@oas.org

COMISION INTER-AMERICANA PARA EL CONTROL DEL ABUSO DE DROGAS / INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION (CICAD)

James F. Mack
Executive Secretary
Tel (202) 458 6221
Fax (202) 458 3658
jmack@oas.org

Anna McG. Chisman
Head, Demand Reduction
Tel: (202) 458-6221
Fax: (202) 458-3658
achisman@oas.org

Dr. Francisco Cumsille
Coordinator, Inter-American Observatory on Drugs
Tel. (202) 458
Fax. (202) 458 3658
fcumsille@oas.org

Luis Alfonzo
Program Specialist, Demand Reduction Area
Tel: (202) 458-3286
Fax: (202) 458-3658
lalfonzo@oas.org

Gloria Wright
Program Specialist, Demanda Reduction Area
Tel: (202) 458 6221
Fax: (202) 458 3658
gwright@oas.org
Maria Paula Luna
Program Specialist, Demand Reduction Area
Tel: (202) 458-6451
Fax: (202) 458-3658
mluna@oas.org
BASIC PRINCIPLES OF THE TREATMENT AND REHABILITATION OF DRUG-ABUSING AND DRUG-DEPENDENT PERSONS IN THE HEMISPHERE
(revised by the CICAD Expert Group on Demand Reduction)

Mexico City
September 29 -- October 1, 2009
BASIC PRINCIPLES OF THE TREATMENT AND REHABILITATION OF DRUG-ABUSING AND DRUG-DEPENDENT PERSONS IN THE HEMISPHERE

Drug dependence is a chronic, relapsing disease that is caused by many factors, both biological, psychological and social, and that must be addressed and treated as a public health matter, on a par with the treatment of other chronic diseases.

The following Basic Principles, derived from scientific research, should therefore govern policies and practice in the provision of drug treatment services:

Accessibility, non-discrimination and respect for human rights

1. Programs for the prevention of drug and alcohol use and for the treatment of abuse and dependence must fully respect the human rights of those participating in them. Treatment programs should be offered in the least restrictive setting possible while assuring the safety of clients and treatment personnel. Clients should be actively involved in determining their own treatment plan, together with the treatment team, on the basis of informed consent.

2. Treatment services should be accessible and located close to those that need them, without discrimination on the grounds of age, gender, race, religion, social or economic condition, or political affiliation.

Drug treatment should be governed by specific protocols based on available scientific evidence

3. Treatment protocols should consist of therapeutic interventions derived from available scientific evidence or, in the absence of convincing evidence, derived from the consensus of treatment experts. These protocols should define the duration of treatment, recommend the therapeutic options that are most appropriate for each individual, and determine the skills required by the various professionals making up the treatment team.

4. Treatment services should be organized as a policy-based treatment system, with a strategic framework to guide the various therapeutic interventions and services, which should be linked in a continuum of care in order to assure continuity, and which should be incorporated into the health system and coordinated with other relevant social sectors, such as housing, social development, job training, education and family support.

5. Treatment services and facilities should be diversified in order, insofar as possible, to match the specific treatment to client needs, on the basis of an assessment. The range of treatment services should include strategies for screening, early
problem detection, clinical diagnosis, motivation to treatment, brief intervention, psychological and medical care, clinical tracking of cases, relapse prevention and aftercare.

6. Treatment should be conceived as a long-term process, in which stakeholders from different disciplines may need to participate, and in which many treatment episodes of different types, in different combinations and for varying periods of time, may be required to achieve therapeutic success.

7. In defining the therapeutic interventions to be offered, the following should be given fundamental consideration: different models of psychotherapies, derived from available scientific evidence or, in the absence of convincing evidence, derived from the consensus of treatment experts; the use of medication when the clinical condition so requires; and, if necessary, a combination of psychotherapy and medication, among other interventions of proven efficacy.

8. Treatment services should incorporate models of care for those persons with drug abuse or dependence problems who present co-morbidity with other mental or physical health problems.

9. The most important tools for the timely identification of individuals at high risk of developing dependence include structured interviews and screening. Interventions and/or treatment in those cases that require follow-up can produce a favorable modification in the course of drug use and its consequences.

10. Treatment programs should include strategies for re-entry into society that will help the client effectively and productively restore his ties to his community.

Organization of treatment services

11. Drug dependence treatment services should be integrated, where possible, into regular health care clinics, settings and systems, to avoid segregation of substance abusers from other types of patients.

12. Care units should be developed for acute complications, especially for management of intoxication and acute withdrawal syndromes; such acute care units are not sufficient on their own, but are a valuable support at different points in any treatment strategy.

13. Community-based treatment options should encourage the participation of the family and community in the therapeutic process, by providing information and guidance to parents, teachers and other significant figures, since they play a key role in achieving and maintaining the success of treatment and social reintegration.
14. Governments should seek means of securing adequate financing for drug treatment programs, to assure the highest quality, greatest accessibility and broadest coverage possible.

**Qualified drug treatment personnel**

15. The proficiency of treatment personnel should be assured by means of systematic selection procedures, and their skills should be improved through specific training programs and periodic refresher courses for professional and non-professional personnel. Treatment services should, as much as possible, be delivered by a multidisciplinary team capable of meeting the various types of care that those needing their services require. Training programs for the accreditation and/or certification of treatment personnel should therefore be promoted.

**Information systems for drug treatment**

16. Strategies should be developed and set in place for ongoing supervision, monitoring, and evaluation of both the structure, operations, efficacy, coverage and cost-benefit of treatment programs, thereby enhancing the quality and appropriateness of the services.

17. The organization of treatment services should be supported by a reliable, timely and flexible information system that includes records of the diagnoses and clinical needs of the patients. The information system should also track changes in symptoms and status, through follow-up on patients to evaluate the outcomes of the therapeutic interventions.
BASIC PRINCIPLES OF THE TREATMENT AND REHABILITATION OF DRUG-ABUSING AND DRUG-DEPENDENT PERSONS IN THE HEMISPHERE
(revised by the CICAD Expert Group on Demand Reduction)

Mexico City
September 29 to October 1, 2009

Drug dependence is a chronic, relapsing disease that must be addressed and treated as a public health matter, on a par with the treatment of other chronic diseases.
The following Basic Principles, derived from scientific research, should therefore govern policies and practice in the provision of drug treatment services:

**Accessibility, non-discrimination and respect for human rights**

18. Programs for the prevention of drug and alcohol use and treatment of abuse and dependence must fully respect the human rights of those participating in them. Clients should be actively involved in determining their own treatment plan, together with the treatment team, on the basis of informed consent.

19. Drug and alcohol treatment services should be accessible and located close to those that need them, without discrimination on the grounds of age, gender, race, religion, or social or economic condition.

**Drug treatment should be governed by specific protocols based on available evidence**

20. Treatment protocols should consist of therapeutic interventions derived from available scientific evidence or, in the absence of convincing evidence, derived from the consensus of treatment experts. These protocols should define the duration of treatment, recommend the most appropriate therapeutic options, and determine the skills required by the various professionals making up the treatment team.

21. Treatment services should be organized as a policy-based treatment system, with a strategic framework to guide the various therapeutic interventions and services, which should be linked in a continuum of care in order to assure continuity of care, and which should be incorporated into the overall health system and coordinated with other relevant social sectors, such as housing, social development, job training, education and family support.

22. Treatment services and facilities should be diversified in order, insofar as possible, to match the specific treatment to client needs, on the basis of an assessment; the range of treatment services should include strategies for screening, early problem detection, clinical diagnosis, brief intervention, motivation to treatment, and clinical tracking of cases.

23. Treatment should be conceived as a long-term process, in which stakeholders from different disciplines participate, and in which multiple interventions of different types may be required to achieve therapeutic success.

24. In defining the therapeutic interventions to be offered, the following should be given fundamental consideration: different models of psychotherapies, derived from available scientific evidence or, in the absence of convincing evidence,
derived from the consensus of treatment experts; the use of medication when the clinical condition so requires; and, if necessary, a combination of psychotherapy and medicinal therapies, among other interventions of proven efficacy.

25. Drug treatment services should incorporate models of care for those persons with drug abuse or dependence problems who present co-morbidity with other mental or physical health problems.

26. The most important tools for the timely identification of individuals at high risk of developing dependence include structured interviews and screening, which, when followed up on with interventions and/or treatments, can produce a favorable modification in the course of drug use.

27. Treatment programs should include strategies for re-entry into society that will help the client effectively and actively restore his ties to his social environment.

**Organization of treatment services**

28. Drug dependence intervention and treatment services should be integrated, where possible, into regular health care clinics, settings and systems, to avoid segregation of substance abusers from other types of patients.

29. Care units should be developed for acute complications, especially for management of intoxication and acute withdrawal syndromes; such acute care units alone are not sufficient, but are a valuable support for any treatment strategy.

30. Community-based treatment options should encourage the participation of the family and community in the therapeutic process, by providing information and guidance to parents, teachers and others, since they play a key role in the success of treatment and social reintegration.

31. Governments should seek means of securing adequate financing for drug treatment programs, to assure the highest quality and broadest coverage possible.

**Qualified drug treatment personnel**

32. The proficiency of treatment personnel should be assured by means of systematic selection procedures, and their skills should be improved through specific training programs, and periodic refresher courses for professional and non-professional personnel. Treatment services should usually [or preferably] be delivered by a multidisciplinary team capable of meeting the various types of care needed by
those asking for their services. Training programs for the accreditation and/or certification of treatment personnel should therefore be promoted.

**Information systems for drug treatment**

33. Strategies should be developed and set in place for ongoing supervision, monitoring, and evaluation of both the structure and operations as well as the effectiveness of treatment programs, thereby enhancing the quality of the services.

34. The organization of treatment services should be supported by an appropriate information system that makes it possible to keep a record of diagnoses and clinical needs of the patients, and track changes in symptoms and status, through follow-up on patients to evaluate the outcomes of the therapeutic interventions.